Forte Capital LLC ADV Has $684,000 Stake in Cencora, Inc. (NYSE:COR)

Forte Capital LLC ADV trimmed its holdings in Cencora, Inc. (NYSE:COR) by 4.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,046 shares of the company’s stock after selling 150 shares during the period. Forte Capital LLC ADV’s holdings in Cencora were worth $684,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Dash Acquisitions Inc. bought a new position in shares of Cencora during the fourth quarter worth approximately $176,000. Concurrent Investment Advisors LLC increased its stake in shares of Cencora by 4.5% during the fourth quarter. Concurrent Investment Advisors LLC now owns 8,046 shares of the company’s stock worth $1,808,000 after purchasing an additional 349 shares during the period. Bryn Mawr Capital Management LLC increased its stake in shares of Cencora by 335.4% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 25,863 shares of the company’s stock worth $5,811,000 after purchasing an additional 19,923 shares during the period. TimesSquare Capital Management LLC increased its stake in shares of Cencora by 2.9% during the fourth quarter. TimesSquare Capital Management LLC now owns 544,248 shares of the company’s stock worth $122,282,000 after purchasing an additional 15,464 shares during the period. Finally, Convergence Investment Partners LLC increased its stake in shares of Cencora by 27.9% during the fourth quarter. Convergence Investment Partners LLC now owns 7,935 shares of the company’s stock worth $1,783,000 after purchasing an additional 1,733 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on COR shares. Robert W. Baird increased their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Mizuho initiated coverage on Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Evercore ISI raised their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Barclays raised their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company raised their price objective on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares in the company, valued at $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by company insiders.

Cencora Trading Down 0.8 %

Shares of COR opened at $241.47 on Friday. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $262.26. The business’s fifty day moving average is $239.52 and its 200-day moving average is $237.46. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm has a market cap of $46.83 billion, a price-to-earnings ratio of 34.35, a PEG ratio of 1.32 and a beta of 0.49.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Friday, February 14th. Cencora’s dividend payout ratio (DPR) is 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.